Apart from ascertaining the efficacy of regorafenib to reduce sorafenib-resistant cell proliferation and viability, we proved for the first time that regorafenib causes FOXO3 downregulation and autophagic flux blockage in sorafenib-resistant HCC. Here, FOXO3 is linked to hepatocellular carcinoma.